NeoGenomics Appoints Former Flatiron Health CEO Carolyn Starrett to Board
NEO has more than doubled off its 52-week low of $4.72 on elevated volume (2.6× avg).
Summary
NeoGenomics has appointed Carolyn S. Starrett, former CEO of Flatiron Health, to its Board of Directors, bringing extensive experience in data, AI, and cancer care to the company.
Key Events · Executive and Board Changes · NEO
-
Board Expansion and New Appointment
The Board of Directors increased its size from nine to ten members and appointed Carolyn S. Starrett as a new director, effective June 23, 2026.
-
Highly Qualified Director Joins
Ms. Starrett brings over 25 years of commercial, product, and operations experience at data and technology companies, with a deep understanding of AI and data insights in cancer care and research. She previously served as CEO of Flatiron Health and as a Board Director at Foundation Medicine.
Analysis · NEO · Industrial Applications And Services
The appointment of Carolyn S. Starrett to NeoGenomics' board is a positive development, adding a director with significant executive and industry-specific expertise. Her background as CEO of Flatiron Health and experience with AI and data insights in cancer care directly aligns with NeoGenomics' focus on oncology diagnostics and precision medicine. This strengthens the board's strategic capabilities as the company continues to expand its portfolio.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 29.9% of the 1591 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.24%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NEO was trading at $12.92 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.7B. The 52-week trading range was $4.72 to $13.74. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.